The demonstration that activation of Nrf2 by TBE-31 ameliorates NASH is consistent with several earlier reports in which pharmacologic activators of Nrf2 including baicalein,62 SFN,63 or Ezetimibe,64 or genetic activation of Nrf2 by expression of a hypomorphic Keap1 allele65 or hepatocyte-specific knockout of Keap1,66 inhibit NASH in rodents caused by an MCD diet or an HF diet. The gene discussed is KEAP1; the disease is metabolic dysfunction-associated steatohepatitis.